Health outcomes and costs in patients prescribed anticholinergic medications for overactive bladder
Journal of Comparative Effectiveness Research · 2026
DOI: 10.57264/cer-2025-0054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2026. Verfasst von Holly E Richter und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics & Gynecology, University of Alabama at Birmingham, Birmingham, AL 35294, USA. Hauptthemen laut MEDLINE: Urinary Bladder, Overactive, Cholinergic Antagonists, Health Care Costs. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Aim
Anticholinergic burden (ACB) is associated with profound clinical and economic burden; however, anticholinergic medications are often prescribed for overactive bladder (OAB). This analysis assessed risk of adverse health outcomes and costs associated with ACB among patients with OAB. Materials & methods: Adults with ≥1 pharmacy claim for ≥1 OAB anticholinergic medication and continuous coverage for ≥6 months before and after the first prescription fill date for OAB anticholinergic medication (index) from January 2010 to November 2021 in the Optum Research Database were included. Daily ACB scores were calculated postindex. The impact of ACB on risk of certain adverse health outcomes was examined using Cox proportional hazards regression with categorical and piecewise linear specifications for ACB. Time-varying total ACB association with healthcare costs was evaluated with marginal structural models.
Results
Overall, 428,142 patients were included in the analysis; mean (SD) age was 65.2 (14.9) years. Mean (SD) preindex ACB was 0.53 (1.44) points/day. Postindex, OAB medications accounted for 61.0% (95% CI: 60.9%–61.1%) of total ACB. Adjusted hazard ratios for urinary tract infection (UTI), urinary retention, delirium/drowsiness, cognitive impairment, falls/fractures and cardiovascular events were >1 (vs 0 points/day) and increased with ACB. A 1-point/day increase in ACB was associated with increased risk of UTI, urinary retention, delirium/drowsiness, cognitive impairment, falls/fractures and cardiovascular events for patients with ACB ≤8 points/day preindex. Increasing ACB was associated with increased all-cause total healthcare costs and costs related to cognitive impairment and falls/fractures.
Conclusion
The association between increased ACB and greater risk of certain adverse health outcomes and costs supports the reassessment of anticholinergic medication use for patients with OAB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics & Gynecology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
- Optum, Eden Prairie, MN 55344, USA.
- Sumitomo Pharma America, Inc., Marlborough, MA 01752, USA.
- Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
- University Hospitals Cleveland Medical Center, Cleveland, OH 44145, USA.
- Seattle Urology Research Center, Seattle, WA 98040, USA.
ORCID-Profile: Holly E Richter, Benjamin Chastek, Adam Carrera, Christina Steiger, Laleh Abedinzadeh, Tim Bancroft, Jeffrey Nesheim, Roger R Dmochowski, Adonis K Hijaz, Jeffrey Frankel
Zitieren
APA
Richter, H. E., Chastek, B., Carrera, A., Steiger, C., Snyder, D., Abedinzadeh, L., Bancroft, T., Nesheim, J., Dmochowski, R. R., Hijaz, A. K., & Frankel, J. (2026). Health outcomes and costs in patients prescribed anticholinergic medications for overactive bladder. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2025-0054
Vancouver
Richter HE, Chastek B, Carrera A, Steiger C, Snyder D, Abedinzadeh L, et al. Health outcomes and costs in patients prescribed anticholinergic medications for overactive bladder. Journal of Comparative Effectiveness Research. 2026. doi:10.57264/cer-2025-0054
BibTeX
@article{Richter2026,
author = {Richter, Holly E and Chastek, Benjamin and Carrera, Adam and Steiger, Christina and Snyder, Daniel and Abedinzadeh, Laleh and Bancroft, Tim and Nesheim, Jeffrey and Dmochowski, Roger R and Hijaz, Adonis K and Frankel, Jeffrey},
title = {Health outcomes and costs in patients prescribed anticholinergic medications for overactive bladder},
journal = {Journal of Comparative Effectiveness Research},
year = {2026},
doi = {10.57264/cer-2025-0054}
}
EUVIMED